GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-04-17| Partnerships

Pyramid Biosciences Bets $1B on Oncology Drug

by Nai Ye Yeat
Share To

The privately-held US biotech Pyramid Biosciences has entered into an exclusive license agreement with China’s GeneQuantum Healthcare to develop and commercialize GQ1010, a potential best-in-class antibody-drug conjugate (ADC) targeting trophoblast cell surface antigen 2 (TROP2).  

Under the terms of the agreement, Pyramid gains exclusive rights to develop and commercialize GQ-1010 globally, excluding greater China (mainland China, Hong Kong, Macau, and Taiwan). In exchange, GeneQuantum will receive an up-front payment of $20 million and up to an additional $1 billion in milestone payments. 

Related article: Pfizer Acquires Seagen for $43 Billion to Capture Leading Position in Oncology 

ADCs, the Next Era of Targeted Therapy

ADCs are a class of drugs designed as a targeted therapy to treat various diseases, but their application is only limited to cancer currently. They are complex molecules consisting of an antibody linked to a biologically active cytotoxic payload or drug. 

Unlike traditional chemotherapy which is often associated with poor therapeutic response and substantial toxicities to normal healthy tissues, antibody-drug conjugates target and kill tumor cells without harming the healthy cells, by integrating the antigen specificity of monoclonal antibodies (mAbs) with antibody fragments. 

To date, more than 10 ADCs have been approved by the FDA, and around a hundred of its kind are under worldwide clinical development.

Key to Expand Oncology Drug Portfolio

GQ1010 utilizes a unique site-specific conjugation technology and incorporates a novel linker payload which may lead to improved stability, safety, and potency of the ADC. Its target, TROP2, is a cell surface glycoprotein highly expressed in a variety of neoplasms, including breast, lung, pancreatic, ovarian, and prostate cancer, and plays a key role in tumor cell proliferation.

GQ1010 is scheduled to enter a first-in-human trial within the next 12 months, providing that the preclinical data has reported a broader therapeutic margin of the drug compared to more advanced TROP2 ADCs.  

If ultimately approved, the drug would rival Gilead’s first-in-class Trop-2-directed antibody-drug conjugate, Trodelvy, that the drugmaker picked up in its $21 billion buyout of Immunomedics in 2020. Trodelvy is currently approved for certain breast cancer treatments as well as advanced urothelial cancer.

Despite the fierce competition in the ADCs market, both companies are optimistic that their partnership will rapidly advance the worldwide development of GQ1010, and help patients overcome their cancer with the success of delivering transformative medicines to those in need.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
World Cancer Day 2025: “United by Unique” – All About Personalized Care
2025-02-04
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
China’s Innovent Biologics Secures USD $1 Billion ADC Oncology Licensing Agreement with Roche
2025-01-06
LATEST
Novo Nordisk Bets Big on CagriSema With A Heavyweight Move Planned for 2026
2025-02-07
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
First-of-its-Kind Diagnostic Aid Uses a Single Hair Strand to Detect Autism Risk in Babies
2025-02-06
Teladoc Dials Up Virtual Care with $70 Million Acquisition of Catapult
2025-02-06
Silicon Valley in the Crosshairs as EU Readies to Strike U.S. Big Tech
2025-02-06
Johnson & Johnson Under Fire Again as Legal Action Over Alleged Talc-Cancer Link Moves to the UK
2025-02-05
MediBuddy Partners with Japan’s ELECOM to Launch Smart Health IoT Devices in India
2025-02-05
EVENT
2025-02-05
Precision Medicine World Conference 2025
Santa Clara, California
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top